Persson S T, Fraser A G, Lane M R
Auckland Hospital.
N Z Med J. 1999 Feb 12;112(1081):28-30.
To audit the success of endoscopic dilatation treatment for oesophageal stricture, to determine any predictive factors for multiple dilatations and to compare data with a previous series from the same department.
The endoscopy records of 121 consecutive patients with benign oesophageal strictures undergoing endoscopic dilatation were reviewed at Auckland Hospital from 1990 to 1994.
Two hundred and thirty-eight procedures were performed with no recorded technical failures and minimal morbidity. The follow-up period from presentation ranged from 18 to 77 months (median 47 months) and the symptom-free period after the last dilatation ranged from 6 to 77 months (median 47 months). One hundred and nineteen patients had been followed for 12 months or more since their last dilatation. Sixty-three patients (52%) required only one dilatation, 44 (36%) patients required two to three dilatations and 14 (12%) patients required more than three dilatations. There was a trend for patients treated with omeprazole to require fewer dilatations than patients treated with H2-receptor antagonists (p = 0.07). Patients with tight strictures (< 11 mm) and Barrett's oesophagus required more dilatations.
Oesophageal dilatation for benign peptic strictures is a safe and effective procedure.
评估内镜下扩张治疗食管狭窄的成功率，确定多次扩张的预测因素，并与同一科室之前的系列研究数据进行比较。
回顾了1990年至1994年奥克兰医院121例连续接受内镜下扩张治疗的良性食管狭窄患者的内镜检查记录。
共进行了238次操作，无技术失败记录，发病率极低。从就诊开始的随访期为18至77个月（中位数47个月），最后一次扩张后的无症状期为6至77个月（中位数47个月）。119例患者自最后一次扩张后已随访12个月或更长时间。63例患者（52%）仅需一次扩张，44例（36%）患者需进行两至三次扩张，14例（12%）患者需进行三次以上扩张。接受奥美拉唑治疗的患者比接受H2受体拮抗剂治疗的患者需要更少扩张的趋势（p = 0.07）。狭窄严重（< 11 mm）的患者和巴雷特食管患者需要更多次扩张。
良性消化性狭窄的食管扩张是一种安全有效的手术。
